Drug Trial Radar · NCT04250922
LAM561 With RT and TMZ for Adults With Glioblastoma
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
144
Actual
Start
Dec 1, 2019
Primary completion
Jan 15, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Laminar PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Laboratory Corporation of America; Northern Institute for Cancer Research, Newcastle; Theradis pharma; LIPODOM THERAPEUTICS
- First posted
- Jan 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.
Conditions
- Primary Glioblastoma
- Glioblastoma Multiforme
Interventions
LAM561Drug
Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase. Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment.
TMZDrug
TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days. During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.
RTRadiation
During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of LAM561 in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.Time frame: Assessed after observing at least 66 PFS events
- To evaluate the efficacy of LAM561 in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.Time frame: Assessed after observing at least 90 OS events
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
Institut Cancerologie de L'Ouest (ICO)
Angers, France
Centre Eugène Marquis (CEM)
Rennes, France
Gustave Roussy University Hospital
Rennes, France
Institut universitaire du cancer
Toulouse, France
Reaserch Fund of the Hadassah Medical Organization
Jerusalem, Israel
Istituto Nazionale Neurologico Carlo Besta
Milan, Italy
Istituto Nazionale Tumori "Regina Elena"
Roma, Italy
University of Turin
Turin, Italy
Istituto Oncologico Veneto IRCCS
Padova, Veneto, Italy
Hospital del Mar
Barcelona, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Hospital Parc Tauli
Sabadell, Spain
Hospital Universitario Reina Sofía
Córdoba, Andalusia, Spain
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
Hospital Clinic
Barcelona, Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Clínico San Carlos
Madrid, Madrid, Spain
Hospital Universitari i Politécnic La Fe.
Valencia, Valencia, Spain
University Hospitals Birmingham NHS Foundation Trust - New Queen Elizabeth Hospital
Birmingham, United Kingdom
Cambridge university hospital
Cambridge, United Kingdom
The Royal Marsden Hospital
London, United Kingdom
Freeman Hospital's Northern Centre of Cancer Care
Newcastle, Newcastle Upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.